**
Recent research from Mount Sinai has revealed alarming levels of per- and polyfluoroalkyl substances (PFAS) in umbilical cord blood, suggesting that fetuses may be exposed to these hazardous chemicals far more than previously recognised. The study, which analysed 120 samples, identified 42 distinct PFAS compounds, indicating a broader range of exposure that could have significant implications for fetal health.
Expanded Analysis Uncovers Hidden PFAS Compounds
Traditionally, tests conducted on umbilical cord blood have focused on a limited number of known PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). However, the recent Mount Sinai study employed an innovative non-targeted analysis approach, which allowed researchers to discover a total of 42 PFAS compounds across their samples. This represents a substantial increase from earlier findings, which typically detected only a handful of these chemicals.
Shelley Liu, co-author of the study and associate professor at the Icahn School of Medicine at Mount Sinai, emphasised the importance of these findings. “It’s particularly crucial to understand the extent of exposure during such a vulnerable period,” Liu noted, underscoring the potential risks to developing fetuses.
The Health Risks Associated with PFAS Exposure
PFAS, often referred to as “forever chemicals” due to their resistance to natural degradation, have been linked to a myriad of health issues, including cancer, birth defects, immune system impairment, and chronic diseases such as kidney disease and high cholesterol. Studies have shown that elevated levels of PFAS in pregnant women correlate with adverse outcomes, including increased infant mortality, low birth weight, and potential long-term health complications like obesity and neurological disorders.
A systematic review encompassing 40 studies found PFAS in nearly every umbilical cord blood sample tested, totalling around 30,000. This pervasive presence raises serious questions about the long-term health implications for children exposed to these substances in utero.
Regulatory Challenges and the Need for Updated Testing Protocols
The findings from this study highlight a significant gap between current regulatory practices and the realities of PFAS contamination. The US Environmental Protection Agency (EPA) typically employs testing methods that only detect a limited number of PFAS compounds—around 30 to 40. In contrast, independent research has identified thousands of PFAS in various environments.
Liu pointed out that while the EPA has recently certified a blood test for 53 compounds, their analysis still missed 31 compounds identified in the Mount Sinai study. This discrepancy suggests that many potentially harmful PFAS are going undetected, resulting in an incomplete understanding of exposure risks.
Implications for Future Research and Policy
Although the Mount Sinai study did not directly link PFAS levels to specific health outcomes, the general correlation between elevated PFAS in blood and health issues cannot be ignored. The research adds to a growing body of evidence indicating that the health risks associated with these chemicals are far-reaching and not yet fully understood.
As David Andrews, acting chief science officer of the Environmental Working Group, remarked, “This paper is a stark reminder of the importance of health-protective regulations.” He stated that the lax oversight of these chemicals could lead to serious health consequences for the next generation.
Why it Matters
The implications of this research extend beyond academic interest; they pose urgent questions about public health and regulatory practices. As awareness of PFAS contamination grows, so too does the call for stronger regulations to protect vulnerable populations, particularly expectant mothers and their unborn children. The findings from Mount Sinai serve as a critical wake-up call, highlighting the need for comprehensive testing and oversight to prevent further exposure to these harmful chemicals, ensuring a healthier future for all.
